NCT03493542 2024-12-31
V501-213
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
9 trialsNCT03721978 2024-10-17
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Inovio Pharmaceuticals
Phase 3 Completed
NCT03185013 2023-07-27
REVEAL 1
Inovio Pharmaceuticals
Phase 3 Completed
NCT02733068 2022-12-19
A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.
Shanghai Zerun Biotechnology Co.,Ltd
Phase 3 Completed
NCT03355820 2020-11-19
A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study
GlaxoSmithKline
Phase 3 Completed
NCT00128661 2019-03-08
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
GlaxoSmithKline
Phase 3 Completed
NCT00337818 2017-05-30
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
GlaxoSmithKline
Phase 3 Completed
NCT00973362 2017-01-06
Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System
Gen-Probe, Incorporated
Phase 3 Completed
NCT00316706 2012-09-18
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
GlaxoSmithKline
Phase 3 Completed